This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Fluocortolone pivalate is a corticosteroid used to treat corticosteroid-responsive dermatoses and hemorrhoids.
- Generic Name
- Fluocortolone pivalate
- DrugBank Accession Number
- DB15777
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Fluocortolone pivalate (DB15777)
- Weight
- Average: 460.586
Monoisotopic: 460.262502454 - Chemical Formula
- C27H37FO5
- Synonyms
- Fluocortolone 21-pivalate
- Fluocortolone trimethylacetate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Hemorrhoids Combination Product in combination with: Lidocaine (DB00281) •••••••••••• ••••••••••• Used in combination for symptomatic treatment of Pain, inflammatory Combination Product in combination with: Lidocaine (DB00281) •••••••••••• ••••• Used in combination for symptomatic treatment of Pain, inflammatory Combination Product in combination with: Lidocaine (DB00281) •••••••••••• ••••• Used in combination to treat Proctitis Combination Product in combination with: Lidocaine (DB00281) •••••••••••• ••••••••••• Used in combination to treat Corticosteroid-responsive dermatosis Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hyperglycemia can be increased when Fluocortolone pivalate is combined with Acarbose. Aceclofenac The risk or severity of gastrointestinal irritation can be increased when Fluocortolone pivalate is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal irritation can be increased when Fluocortolone pivalate is combined with Acemetacin. Acenocoumarol Fluocortolone pivalate may increase the anticoagulant activities of Acenocoumarol. Acetohexamide The risk or severity of hyperglycemia can be increased when Fluocortolone pivalate is combined with Acetohexamide. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DOLOPROCT Fluocortolone pivalate (0.1 %) + Lidocaine hydrochloride anhydrous (2 %) Cream Rectal Karo Pharma Ab 2014-07-08 2023-06-16 Italy 
DOLOPROCT Fluocortolone pivalate (0.1 %) + Lidocaine hydrochloride anhydrous (2 %) Cream Rectal Karo Pharma Ab 2014-07-08 2023-06-16 Italy DOLOPROCT Fluocortolone pivalate (0.1 %) + Lidocaine hydrochloride anhydrous (2 %) Cream Rectal Karo Pharma Ab 2014-07-08 2023-06-16 Italy Doloproct 0,1 % + 2 % Rektalcreme Fluocortolone pivalate (2 %) + Lidocaine hydrochloride (0.1 %) Cream Rectal Karo Pharma Ab 2005-12-21 Not applicable Austria 
Doloproct 1 mg + 40 mg Zäpfchen Fluocortolone pivalate (1 mg) + Lidocaine hydrochloride (40 mg) Suppository Rectal Karo Pharma Ab 2005-12-20 Not applicable Austria
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9J8AL6K50Q
- CAS number
- 29205-06-9
- InChI Key
- XZBJVIQXJHGUBE-HZMVJJPJSA-N
- InChI
- InChI=1S/C27H37FO5/c1-14-9-17-16-11-19(28)18-10-15(29)7-8-26(18,5)23(16)20(30)12-27(17,6)22(14)21(31)13-33-24(32)25(2,3)4/h7-8,10,14,16-17,19-20,22-23,30H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,22-,23-,26+,27+/m1/s1
- IUPAC Name
- 2-[(1S,2R,3aS,3bS,5S,9aR,9bS,10S,11aS)-5-fluoro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl 2,2-dimethylpropanoate
- SMILES
- [H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
References
- General References
- INVIMA Product Information: SCHERIPROCT (fluocortolone pivalate and lidocaine HCl) topical cream [Link]
- External Links
- ChemSpider
- 107027
- 4465
- ZINC
- ZINC000030691645
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Rectal Solution Topical Cream Topical Emulsion Topical Lotion Topical Ointment Topical Ointment Rectal Cream Suppository Rectal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0022 mg/mL ALOGPS logP 3.05 ALOGPS logP 4.21 Chemaxon logS -5.3 ALOGPS pKa (Strongest Acidic) 15.15 Chemaxon pKa (Strongest Basic) -0.23 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 80.67 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 124.32 m3·mol-1 Chemaxon Polarizability 50.5 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-052f-1006900000-50954faba41b4f53fd39 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0401900000-68ebd7352eb90dd05f1d Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-7019400000-3d94eaffbdde8e96884e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0udm-3509000000-2aeb07e98a07c94eb905 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-066r-6579200000-b05d96db254cb49ba08d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-2009100000-c4fabd185cf996434976 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 21, 2020 16:36 / Updated at May 14, 2021 01:07